about bpl

Bio Products Laboratory Ltd.


PRESS RELEASE: Bio Products Laboratory Receives European Approval for Coagadex® ▼ (Human Coagulation Factor X) First-ever treatment for rare bleeding disorder ‘hereditary factor X deficiency'

NEWS RELEASE: March 17 th 2016     ELSTREE, UK Bio Products Laboratory, Limited (BPL) today announced that the European Medicines Agency has granted marketing authorisation for Coagadex. Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for ...

Date added: Thursday 17th March 2016
Latest updated: Wednesday 8th February 2017

Patient information leaflets